Navigation Links
A Window Into Parkinson's Disease
Date:11/12/2008

NEW YORK, Nov. 12 /PRNewswire-USNewswire/ -- A new study being published in this Friday's online edition of Cell will help answer the question, what causes Parkinson's disease?

One of the most pressing questions in the medical research into Parkinson's disease is what causes the sensitive cells in the brain to die in the first place. Answering this question has been especially difficult because there are two nearly identical types of brain cells that produce dopamine and they are mixed together in the same brain regions. However, only one cell type is affected in Parkinson's, the other is spared. Scientists have wanted to compare these closely related brain cells in the hope that differences between the two would explain why the sensitive cells die. This understanding will suggest opportunities for intervention.

The main obstacle has been the infeasibility of separating the two cell types for analysis. Doctors Paul Greengard and Myriam Heiman of The Michael Stern Parkinson's Disease Foundation and their colleagues at The Rockefeller University have developed a system that solves this fundamental technological problem. These scientists have focused on discovering which genes are turned on or off in the two similar cell types. If one views a cell as a computer, then the genes can be viewed as software. Unique programs operate depending on which genes are turned on. When genes are "turned on", they cause the cell to produce specific proteins.

What makes cells vulnerable to Parkinson's disease depends largely on the kinds and amounts of proteins they produce, or their "translational profile."

The new method discovered by Greengard, Heiman, and colleagues, Translating Ribosome Affinity Purification (TRAP), reveals translational profiles in cells by isolating the genetic messages as they pass through the protein production factories called ribosomes.

This new technique will help propel the scientific community, which has struggled
'/>"/>

SOURCE The Michael Stern Parkinson?s Research Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
2. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
3. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
4. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
5. Physicians Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease
6. Michael J. Fox Foundation Announces $11 Million in 2009 Funding for Translational, Pre-Clinical and Clinical Parkinsons Disease Research
7. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
8. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
9. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
10. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... genetic variation that may indicate a patient,s risk of ... certain pharmaceutical therapies or chemicals is one of several ... (NYSE: DGX ) will present during the ... Exposition, December 5-8, 2009, in New Orleans, LA. ...
(Date:12/3/2009)... Dec. 3 BioMed Realty Trust, Inc. (NYSE: ... new lease with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) ... office space at The Landmark at Eastview campus in Tarrytown, ... This lease of additional space was completed approximately two months ...
(Date:12/3/2009)... DIEGO, California, December 3 , ... for,Hepatitis C Viral Replication, Thereby Significantly Reducing Hepatitis C,Virus ... C Virus , - SPC3649 ... Serious Adverse Events in the Treated Animals - Signaling ...
Breaking Medicine Technology:Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 2BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Researchers shed light on trading behavior in animals and humans 8746 1Researchers shed light on trading behavior in animals and humans 8746 2Fossil teeth of browsing horse found in Panama Canal earthworks 8744 1Fossil teeth of browsing horse found in Panama Canal earthworks 8744 2New research program BioInterfaces launched 8742 1New research program BioInterfaces launched 8742 2
... Call on Monday, December 10, 2007, NEW HAVEN, ... ) today announced that preliminary data,from its pivotal Phase ... novo acute myelogenous leukemia (AML) would be presented,in a ... Meeting in,Atlanta, Georgia on Saturday, December 8, 2007., ...
... RDYN ) announced today that President and Chief ... and Powerful Anti-infectives,panel at the RBC Capital Markets 2007 ... am ET on Thursday, December 13, 2007 at,the Westin ... audio webcast of the panel discussion will be available ...
Other Medicine Technology:Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting 2Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting 3
(Date:12/6/2009)... Dec. 6 Sickle cell disease, a ... cells, is one of the most common genetic ... world, including more than 70,000 Americans.(1) Research presented ... American Society of Hematology highlights intriguing studies on ... for children with this blood disorder, evaluations of ...
(Date:12/6/2009)... dangerous substances such as asbestos have been found in toys in ... ... December 6, 2009 -- As parents shop for children,s toys during ... due to lead paint or asbestos contamination, says a New York ... rooms each year due to toy-related injuries,” says Joseph W. Belluck, ...
(Date:12/5/2009)... Type of Blood Cancer Is Most Challenging-- ... oncologists have identified specific genes, dubbed partner genes, that ... of leukemia in infants. By more accurately defining specific ... may benefit from particular treatments. ,, Oncologists also ...
(Date:12/5/2009)... today announced the launch of International Solutions, an innovative new international ... its UK equivalent. In addition to offering customers the flexibility to ... needs and budgets, International Solutions enables customers to tailor their benefits ... , ...
(Date:12/4/2009)... Dec. 4 Thousands of KPMG LLP employees came together ... a community service event which combines the audit, tax and ... "This national service day reflects our firm,s long history of ... spirit of caring to brighten the holidays for some children," ...
Breaking Medicine News(10 mins):Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2
... The Arizona State University College ... will host the first national Healthcare Innovation Challenge(R) ... Inc. ( http://www.ideacrossing.com ), a firm that helps ... will be conducted from January 20 to May ...
... health care highly as part of efforts to stem ... reforming health care as one of the top priorities ... national survey conducted by researchers from the Kaiser Family ... Americans rank helping the newly unemployed afford health insurance ...
... patients and physicians who have been shortchanged , ... Medical Association (AMA), along with the Medical Society of ... Medical Association, claims victory with the settlement agreement reached ... $350 million settlement marks the largest monetary settlement of ...
... HOUSTON, Jan. 15 The $800 million settlement that Eli,Lilly ... pay to settle civil False Claims,Act charges related to allegedly ... can be traced to the courageous stands taken by,employee whistleblowers, ... The company,s settlement with the federal government, ...
... Jan. 15, 2009 The Procter & Gamble,Company (NYSE: ... changes: , -- Mariano Martin, ... 30, 2009, after 33 years of service. He will ... when he will focus on working,closely with his successor ...
... Jan. 15 In a lawsuit pending in Wayne ... Detroit-based OmniCare, a,once-large HMO servicing Medicaid recipients, several major ... their claim for $75 Million in,damages from United American ... In their filing, the Provider ...
Other Medicine News:Health News:Arizona State University Nursing and Idea Crossing Partner to Conduct First National Healthcare Innovation Challenge 2Health News:Health provisions among public's top priorities for economic stimulus 2Health News:Health provisions among public's top priorities for economic stimulus 3Health News:Health provisions among public's top priorities for economic stimulus 4Health News:Health provisions among public's top priorities for economic stimulus 5Health News:AMA Claims Victory With Record Breaking Settlement in Case Against Insurer 2Health News:Whistleblowers' Complaints Lead Eli Lilly to Pay $800 Million to Settle Civil Medicaid Fraud Charges, According to Berg & Androphy 2Health News:Procter & Gamble Announces Organizational Changes 2Health News:Detroit Area Hospitals Seek $75 Million from United American HealthCare Arising out of its Management of the Liquidated OmniCare HMO 2
Inquire...
Inquire...
Bench Top Class I Containment Cabinet Personnel Protection...
Class II Type B1 Biological Safety Cabinet...
Medicine Products: